Radioimmunotherapy in Lymphomas

Reem Karmali; Stephanie A. Gregory

doi:10.1002/9781118589199.ch62

Radioimmunotherapy in Lymphomas

Reem Karmali^*, Stephanie A. Gregory

^*Corresponding author for this work

Medicine, Hematology Oncology Division

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Radioimmunotherapy (RIT) studies demonstrate favorable efficacy and safety profiles in follicular lymphoma with the primary toxicity being reversible myelosuppression. Many studies have demonstrated higher overall response rates and durations of response when used earlier in the treatment algorithm for follicular or indolent lymphoma. This chapter asks a number of questions that will drive home the nuances of RIT use. It commences with a discourse on the criteria which excludes a patient from receiving RIT. The consolidation in aggressive lymphomas are encouraging but should not be adopted as a standard approach outside of a clinical trial.

Original language	English (US)
Title of host publication	Cancer Consult
Subtitle of host publication	Expertise for Clinical Practice
Publisher	Wiley-Blackwell
Pages	398-402
Number of pages	5
ISBN (Electronic)	9781118589199
ISBN (Print)	9781118589212
DOIs	https://doi.org/10.1002/9781118589199.ch62
State	Published - Jun 20 2014

Keywords

Follicular lymphoma
Lymphomas
Mantle cell lymphoma (MCL)
Radioimmunotherapy (RIT)

ASJC Scopus subject areas

Medicine(all)

Access to Document

10.1002/9781118589199.ch62

Cite this

@inbook{a509fca6904545f3addc90623ca1c727,

title = "Radioimmunotherapy in Lymphomas",

abstract = "Radioimmunotherapy (RIT) studies demonstrate favorable efficacy and safety profiles in follicular lymphoma with the primary toxicity being reversible myelosuppression. Many studies have demonstrated higher overall response rates and durations of response when used earlier in the treatment algorithm for follicular or indolent lymphoma. This chapter asks a number of questions that will drive home the nuances of RIT use. It commences with a discourse on the criteria which excludes a patient from receiving RIT. The consolidation in aggressive lymphomas are encouraging but should not be adopted as a standard approach outside of a clinical trial.",

keywords = "Follicular lymphoma, Lymphomas, Mantle cell lymphoma (MCL), Radioimmunotherapy (RIT)",

author = "Reem Karmali and Gregory, {Stephanie A.}",

year = "2014",

month = jun,

day = "20",

doi = "10.1002/9781118589199.ch62",

language = "English (US)",

isbn = "9781118589212",

pages = "398--402",

booktitle = "Cancer Consult",

publisher = "Wiley-Blackwell",

}

TY - CHAP

T1 - Radioimmunotherapy in Lymphomas

AU - Karmali, Reem

AU - Gregory, Stephanie A.

PY - 2014/6/20

Y1 - 2014/6/20

N2 - Radioimmunotherapy (RIT) studies demonstrate favorable efficacy and safety profiles in follicular lymphoma with the primary toxicity being reversible myelosuppression. Many studies have demonstrated higher overall response rates and durations of response when used earlier in the treatment algorithm for follicular or indolent lymphoma. This chapter asks a number of questions that will drive home the nuances of RIT use. It commences with a discourse on the criteria which excludes a patient from receiving RIT. The consolidation in aggressive lymphomas are encouraging but should not be adopted as a standard approach outside of a clinical trial.

AB - Radioimmunotherapy (RIT) studies demonstrate favorable efficacy and safety profiles in follicular lymphoma with the primary toxicity being reversible myelosuppression. Many studies have demonstrated higher overall response rates and durations of response when used earlier in the treatment algorithm for follicular or indolent lymphoma. This chapter asks a number of questions that will drive home the nuances of RIT use. It commences with a discourse on the criteria which excludes a patient from receiving RIT. The consolidation in aggressive lymphomas are encouraging but should not be adopted as a standard approach outside of a clinical trial.

KW - Follicular lymphoma

KW - Lymphomas

KW - Mantle cell lymphoma (MCL)

KW - Radioimmunotherapy (RIT)

UR - http://www.scopus.com/inward/record.url?scp=84946433633&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946433633&partnerID=8YFLogxK

U2 - 10.1002/9781118589199.ch62

DO - 10.1002/9781118589199.ch62

M3 - Chapter

AN - SCOPUS:84946433633

SN - 9781118589212

SP - 398

EP - 402

BT - Cancer Consult

PB - Wiley-Blackwell

ER -

Radioimmunotherapy in Lymphomas

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this